LAVA Therapeutics N.V. (LVTX)
NASDAQ: LVTX
· Real-Time Price · USD
1.52
-0.02 (-1.30%)
At close: Aug 15, 2025, 3:59 PM
1.52
-0.33%
After-hours: Aug 15, 2025, 04:04 PM EDT
LAVA Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -3.48M | -4.13M | -12.2M | -8.3M | -553K | -6.44M | -8.79M | -12.6M | -13.87M | -14.93M | 1.04M | -7.28M | -10.5M | -12.13M | -9.22M | -8.48M | -22.82M |
Depreciation & Amortization | -456K | -220K | 212K | 228K | 247K | 352K | 318K | 295K | 313K | 271K | 168K | 174K | 168K | 374.87K | 183.76K | 1.22K | 79.97K |
Stock-Based Compensation | 540K | 590K | 720K | 821K | 1.09M | 925K | 924K | 1.56M | 1.63M | 906K | 841K | 378K | 2.23M | 1.62M | 1.4M | 1.22M | 744.57K |
Other Working Capital | n/a | 3.74M | 2.37M | -1.8M | -424K | -938K | -5.49M | -3.51M | 4.1M | 45.98M | -18.54M | 781K | 781K | 2.1M | -1.19M | -1.29M | -1.27M |
Other Non-Cash Items | n/a | -1.59M | 1.43M | -158K | -1.33M | 1.15M | -1.46M | -661K | 476K | 3.57M | -2.62M | -3.65M | -359K | 501.06K | 74.1K | 234.19K | 358.5K |
Deferred Income Tax | n/a | 240K | -96K | -85K | -69K | -60K | -51K | -97K | -71K | -68K | -46K | -75K | -60K | -66.22K | -49.52K | -37.15K | -28.96K |
Change in Working Capital | n/a | 3.79M | 1.3M | -894K | -581K | -6.05M | 1.6M | -1.56M | 3.19M | 45.98M | -13.67M | 914K | 886K | 2.77M | -1.41M | -5.45M | 16.71M |
Operating Cash Flow | 2.02M | -1.41M | -8.63M | -8.38M | -1.13M | -10.12M | -7.45M | -13.06M | -8.34M | 35.73M | -14.34M | -9.72M | -7.63M | -6.93M | -9.02M | -12.51M | -4.96M |
Capital Expenditures | n/a | n/a | -23K | n/a | n/a | 8.76K | -6K | -224K | -500K | -265K | 25K | -24K | -323K | -208.66K | -568.17K | 72.37K | -188.9K |
Cash Acquisitions | n/a | -8.2K | n/a | n/a | 89K | n/a | 15.93M | -410.55K | n/a | 3.62M | -6.69M | -3.39M | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | -4.95M | -21.52M | -19.53M | -31.44M | -24.37M | -36.19M | -29.34M | -24.55M | n/a | -24.33M | -7.94M | -21.37M | -17.24M | -3.62M | n/a | n/a | n/a |
Sales Maturities Of Investments | 20.11M | 32.5M | 20M | 31.77M | 25M | 27.5M | 12.5M | 25M | 8.18M | 20.45M | 14.49M | 24.93M | 20.93M | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | -6K | 2K | 6.86K | 89K | -8.76K | -15.93M | 410.55K | 7.54M | -3.62M | 6.69M | 3.39M | n/a | 2.85M | -48.86M | 10.87K | n/a |
Investing Cash Flow | 15.16M | 10.97M | 447K | 339K | 718K | -8.69M | -16.85M | 224K | 7.68M | -4.14M | 6.58M | 3.53M | 3.37M | -986.1K | -49.43M | 83.24K | -188.9K |
Debt Repayment | n/a | -206K | -370K | -12K | -8K | 120.2K | -137K | -157K | -97K | -16K | -7K | 21K | 270K | -546.17K | 216K | 202K | 84K |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 161.12K | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -1.92M | -71.49M |
Other Financial Acitivies | n/a | -193.66K | 2K | 17K | 8K | -300.2K | n/a | n/a | n/a | n/a | n/a | 15K | n/a | -0.02 | -4.1M | 1.78M | n/a |
Financial Cash Flow | n/a | -206K | -368K | 5K | n/a | -180K | -137K | -157K | -97K | -16K | -7K | 36K | 270K | 1.51M | -3.88M | 7.41M | 172.8M |
Net Cash Flow | 4.66M | 8.05M | -8.12M | -8.1M | -1.04M | -18.43M | -24.94M | -13M | 271K | 36M | -11.54M | -9.86M | -5.15M | -10.76M | -60.8M | -6.19M | 168.03M |
Free Cash Flow | 2.02M | -1.41M | -8.65M | -8.38M | -1.13M | -10.11M | -7.46M | -13.29M | -8.84M | 35.47M | -14.32M | -9.74M | -7.95M | -7.14M | -9.58M | -12.44M | -5.15M |